Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors

Inclusion Criteria: * They are at least 50 years of age; * Have been diagnosed with chronic lymphocytic leukemia (CLL) OR Waldenström's macroglobulinemia (WM) * Have been on first-line BTK inhibitor (ie ibrutinib or acalabrutinib) for at least 3 months, * Prior treatment with single agent rituximab is permitted if last dose was administered over one year ago; * Have at least a one-year life expectancy; * Have a history of varicella (chicken-pox) OR lived in the US or any endemic country for \> 30 years. * Prior radiation therapy is allowed Exclusion Criteria: * They have a known hypersensitivity to a vaccine component; * Had herpes zoster reactivation within the past year; * Had received or were scheduled to receive a live virus vaccine in the period from 4 weeks prior to Dose 1 through 28 days post-second dose; * Had received or were scheduled to receive an inactivated vaccine in the period ranging from 7 days prior to Dose 1 through 7 days post- second dose; * Are unable to give informed consent; * Have absolute lymphocyte counts greater than 20,000 X 109/L; * Are receiving treatment for CLL or WM with an additional agent other than a BTK inhibitor; * Had rituximab treatment within a year prior to study start; * Had prior chemotherapy.